FT Global Pharma and Biotech Summit

The FT Global Pharma and Biotech Summit returns in 2026 to examine the forces reshaping the pharmaceutical and biotechnology industries, with a programme centred on artificial intelligence, dealmaking, and clinical development.

AI in life sciences, dealmaking, and clinical trial agility on the agenda

The summit's stated programme spans three interconnected themes: AI in life sciences, dealmaking trends, and clinical trial agility. These reflect the strategic questions currently occupying senior leadership across pharma and biotech, from how machine learning is being embedded in drug discovery pipelines to how licensing and M&A activity is evolving in a tighter capital environment. The clinical trial agility strand points to ongoing industry pressure to accelerate development timelines without compromising data integrity.

Where business development and R&D leadership converge

The breadth of the programme, spanning AI adoption, deal structures, and trial design, positions this summit at the intersection of R&D strategy and commercial decision-making. For business development leads and R&D heads evaluating partnership or in-licensing opportunities, the dealmaking and AI tracks offer a concentrated read on where the industry is placing its bets heading into 2027.

Registration is open via the event website, with the summit scheduled across two days in November 2026.